Who Is Michael Halstead? Chief Executive of Helus Pharma
Executive profile and background of Helus Pharma chief executive Michael Halstead.
Michael Halstead is the chief executive of Helus Pharma, having been officially appointed to the position on August 3, as reported by ad-hoc-news.de.
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
He brings 25 years of pharmaceutical industry experience, having previously served as President of Intra-Cellular Therapies, Inc. and held senior leadership roles at Warner Chilcott plc, according to markets.financialcontent.com.
Where Michael Halstead Is Now
- Current Role: Chief executive
- Organization: Helus Pharma
- Known For: Overseeing commercial biopharmaceutical development, including the commercialization of CAPLYTA (lumateperone) and major corporate transactions
- Recent News: Appointed chief executive on August 3, succeeding Eric So
Michael Halstead serves as chief executive of Helus Pharma, taking over leadership following an interim period led by Eric So, as documented by ad-hoc-news.de.
Career History and Background
Michael Halstead has accumulated 25 years of experience in the pharmaceutical industry. He formerly served as President of Intra-Cellular Therapies, Inc., where he helped transform the organization from an early-stage clinical development company into a fully integrated commercial biopharmaceutical enterprise, according to markets.financialcontent.com. During his tenure there, he was instrumental in the development, launch, and commercialization of CAPLYTA (lumateperone), supported pipeline programs targeting generalized anxiety disorder and neuropsychiatric symptoms associated with Alzheimer's disease, managed multiple equity offerings, and led the company's $14.6 billion sale to Johnson & Johnson in 2025.
Prior to his work at Intra-Cellular Therapies, Halstead held senior leadership roles at Warner Chilcott plc. In that capacity, he oversaw Warner Chilcott's $3 billion acquisition of Procter & Gamble's pharmaceutical business in 2009, oversaw the integration of roughly 2,000 employees from that business, and oversaw the company's $8.5 billion sale to Actavis in 2013, as detailed by markets.financialcontent.com.
Halstead holds a B.A. in International Relations from Boston University and earned a J.D. from Villanova University Charles Widger School of Law, as reported by markets.financialcontent.com.
Statements on Helus Pharma
Upon joining Helus Pharma, Halstead stated that he was honored to join the team at a crucial stage in the company's evolution, according to markets.financialcontent.com.
Halstead also stated that clinical results in the HLP003 program suggest the potential to transform the treatment paradigm for major depressive disorder. In addition, he stated that Helus Pharma's intellectual property portfolio of more than 350 patent applications and more than 100 granted patents worldwide provides a solid foundation for growth, as reported by markets.financialcontent.com.
Recent and Upcoming Engagements
In September 2026, Halstead was scheduled to represent Helus Pharma at multiple industry conferences. He was scheduled to participate in a fireside chat at the Cantor Global Healthcare Conference in New York City on September 11, 2026, according to The Globe and Mail.
He was also scheduled for a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 16, 2026, as reported by Nasdaq. Furthermore, Halstead was scheduled to take part in a virtual fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026, according to Nasdaq.
Frequently asked questions
Who is Michael Halstead?
Michael Halstead is a pharmaceutical executive with 25 years of industry experience who was appointed chief executive of Helus Pharma on August 3.
What role did Michael Halstead hold before joining Helus Pharma?
Halstead formerly served as President of Intra-Cellular Therapies, Inc., and earlier held senior leadership roles at Warner Chilcott plc.
What major transactions has Michael Halstead managed in his career?
Halstead led Intra-Cellular Therapies' $14.6 billion sale to Johnson & Johnson in 2025. At Warner Chilcott, he oversaw the $3 billion acquisition of Procter & Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in 2013.
What is Michael Halstead's educational background?
Halstead earned a B.A. in International Relations from Boston University and a J.D. from Villanova University Charles Widger School of Law.
Whom did Michael Halstead succeed as chief executive at Helus Pharma?
Halstead succeeded Eric So, who had steered Helus Pharma on an interim basis since April 20.
What has Michael Halstead stated about Helus Pharma's HLP003 program?
Halstead stated that clinical results in the HLP003 program suggest the potential to transform the treatment paradigm for major depressive disorder.
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Michael Halstead or Helus Pharma. See more people in psychedelic medicine.